Drug Profile
Anti-CD19/CD20 chimeric antigen receptor T cell therapy - Shanghai Longyao Biotechnology
Alternative Names: Mixed CD19/CD20 CAR-T cells therapy - Shanghai Longyao BiotechnologyLatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Shanghai Longyao Biotechnology
- Developer Shanghai Jiao Tong University; Shanghai Longyao Biotechnology; Xuzhou Medical University
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II B-cell lymphoma
Most Recent Events
- 28 May 2021 No recent reports of development identified for phase-I development in B-cell lymphoma(In adolescents, In the elderly, Second-line therapy or greater, In adults) in China (IV, Infusion)
- 04 Apr 2018 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater, In adolescents, In adults, In the elderly) in China (IV) (NCT03576807)
- 01 Mar 2017 Phase-I/II clinical trials in B-cell lymphoma (Second-line therapy or greater) in China (Parenteral) (NCT03207178)